Coagulopathy — Mastery Guide

🩸 Coagulopathy — Mastery Guide

Diagnosis, Correction, Reversal, and ICU Strategy in All Settings

📘 Part of the Hematologic Emergencies in Critical Care Series

Prepared for Dr. Amir Fadhel – Specialist in Anesthesiology and Critical Care
🗓️ Created on: 06/06/2025

📖 About This Guide

Developed in collaboration with Sophia (ChatGPT-4o), this teaching guide is part of a distinguished clinical series that follows the acclaimed ABG, Shock, Mechanical Ventilation, ARDS, and Neurologic Emergency guides.

This edition is designed to meet the expectations of consultants, intensivists, and academic examiners at institutions such as the Mayo Clinic, Cleveland Clinic, and the Royal College of Anaesthetists (UK).

💡 What Sets This Guide Apart?

Meticulous, structured analysis of coagulopathy in ICU, trauma, liver failure, and sepsis
Stepwise diagnostic reasoning from platelet to fibrinolysis
High-level clinical integration of labs (PT, aPTT, INR, D-dimer, fibrinogen, viscoelastic testing)
Precision correction protocols including warfarin, DOACs, DIC, HIT, thrombocytopenia
Resource-adaptable strategies for both high-income and low-resource hospitals
FRCPath/FICM-style MCQs and oral exam pearls

This guide is crafted to not only match the academic rigor of fellowship exams, but to serve as an indispensable bedside tool for clinicians managing hemorrhage, thrombosis, and complex coagulation disorders.

📚 Table of Contents — Coagulopathy Mastery Guide

1️⃣ Understanding Hemostasis — Physiology & Key Concepts
▫️ Primary, secondary hemostasis & fibrinolysis
▫️ Role of endothelium, platelets, and clotting factors

2️⃣ Laboratory Evaluation of Coagulation
▫️ PT, aPTT, INR, TT, fibrinogen, D-dimer
▫️ Mixing studies & viscoelastic testing (TEG/ROTEM)

3️⃣ Approach to Bleeding in the ICU
▫️ Structured clinical reasoning
▫️ Transfusion triggers and real ICU examples

4️⃣ Thrombocytopenia in the ICU — Diagnosis & Management
▫️ Quantitative vs qualitative platelet disorders
▫️ Heparin-Induced Thrombocytopenia (HIT vs HAT)
▫️ Immune Thrombocytopenic Purpura (ITP)
▫️ Thrombotic Thrombocytopenic Purpura (TTP)
▫️ Transfusion thresholds and expected responses

5️⃣ Inherited Coagulation Disorders
▫️ Hemophilia A & B, von Willebrand disease
▫️ Factor replacement, DDAVP, cryoprecipitate

6️⃣ Acquired Coagulopathies in Critical Care
▫️ DIC (diagnosis, scoring, stages)
▫️ Liver dysfunction, uremia, malignancy
▫️ Massive transfusion and dilutional effects

7️⃣ Anticoagulant-Associated Coagulopathy
▫️ Warfarin, DOACs, heparins — reversal strategies
▫️ PCC, vitamin K, idarucizumab, andexanet alfa

8️⃣ Coagulopathy in Special Situations
▫️ Trauma, obstetric hemorrhage, HELLP, AFE
▫️ ECMO, cardiac surgery, and post-operative states

9️⃣ Thrombotic vs Hemorrhagic Risk in the ICU
▫️ Sepsis, COVID-19, malignancy, and VTE prophylaxis
▫️ When to anticoagulate vs when to transfuse

🔟 Management Algorithms & Protocols
▫️ Institutional pathways
▫️ Emergency correction workflows

1️⃣1️⃣ Managing Coagulopathy in Limited-Resource Settings
▫️ Diagnosis without labs
▫️ Workarounds without PCC or factor concentrates
▫️ Pragmatic transfusion strategies in rural ICUs

1️⃣2️⃣ High-Yield Tables & Drug Doses
▫️ Platelet, FFP, cryo, PCC — exact replacement regimens
▫️ INR correction, DIC scoring, reversal cheat sheets

1️⃣3️⃣ Pocket Summary & Mnemonics
▫️ 4Ts of HIT, DIC mnemonic, bleeding checklists

1️⃣4️⃣ Advanced MCQ Bank — 15 Critical Care Questions
▫️ FRCPath-style, ICU-based, with explanations

1️⃣5️⃣ Final Words & Mastery Series Access

1️⃣ Understanding Hemostasis — Physiology & Key Concepts

The balance between clot and flow — where it all begins.

🧬 What Is Hemostasis?

Hemostasis is the finely tuned physiological process that:

Prevents excessive bleeding following vascular injury
Maintains blood in a fluid state within vessels
Ensures clot dissolution once healing begins

It’s an elegant balance between procoagulant, anticoagulant, and fibrinolytic forces.

⚙️ Phases of Hemostasis

Vascular Phase
▫️ Immediate vasoconstriction after injury
▫️ Endothelial cells expose collagen and tissue factor
Primary Hemostasis
▫️ Platelet adhesion (via von Willebrand Factor)
▫️ Platelet activation and aggregation
▫️ Forms the platelet plug
▫️ Timeframe: Seconds to minutes
Secondary Hemostasis
▫️ Activation of coagulation cascade
▫️ Formation of fibrin mesh stabilizing the platelet plug
▫️ Requires clotting factors (e.g., thrombin, factor VIII, fibrinogen)
Fibrinolysis
▫️ Controlled breakdown of the clot
▫️ Plasminogen → Plasmin
▫️ Prevents thrombosis and vessel occlusion

🔁 Interplay Between Systems

Component	Key Players
Procoagulants	Tissue factor, thrombin, fibrinogen
Anticoagulants	Antithrombin III, Protein C & S, TFPI
Fibrinolytics	Plasmin, tPA
Platelet-related	vWF, ADP, thromboxane A₂, glycoprotein IIb/IIIa

🧠 Endothelial cells are not passive! They release prostacyclin (PGI₂), NO, and tPA — keeping blood smooth and slippery until injury occurs.

🩸 The Coagulation Cascade — Simplified

Pathway	Trigger	Measured by	Key Factor
Intrinsic	Collagen, platelets	aPTT	Factor XII → XI → IX
Extrinsic	Tissue factor (TF)	PT / INR	Factor VII
Common	Convergence point	PT/aPTT	Factor X → II → I

⚠️ The common pathway is the critical bridge to thrombin (IIa) and fibrin (Ia) formation.

🧪 Fibrin Cross-Linking & Stabilization

Thrombin (IIa) → converts fibrinogen (I) to fibrin (Ia)
Factor XIIIa → cross-links fibrin for stable clot
Clot forms in 5–10 minutes under normal physiology

🧠 Clinical Insight

Primary hemostasis defects → mucocutaneous bleeding, petechiae, epistaxis
Secondary hemostasis defects → deep tissue bleeding, hemarthrosis, surgical site oozing
Combined defects (e.g., DIC) → both patterns + shock

2️⃣ Laboratory Evaluation of Coagulation

Numbers with meaning. Patterns that reveal the cause.

🧪 Core Coagulation Tests — Overview

Test	What It Measures	Primary Use
PT (Prothrombin Time)	Extrinsic + common pathway (Factors VII, X, V, II, I)	Warfarin monitoring, liver disease
INR	Standardized PT	Anticoagulation adjustment (warfarin)
aPTT	Intrinsic + common pathway (Factors XII, XI, IX, VIII, X, V, II, I)	Heparin monitoring, hemophilia
TT (Thrombin Time)	Conversion of fibrinogen to fibrin	Detects heparin effect, dysfibrinogenemia
Fibrinogen	Quantitative fibrinogen (Factor I)	DIC, liver disease, bleeding screen
D-dimer	Fibrin degradation product	DIC, thrombosis, COVID-19

🔍 How to Interpret Coagulation Labs

Isolated Prolongation	Likely Cause
↑ PT / INR only	Warfarin, Factor VII deficiency, early liver disease
↑ aPTT only	Heparin, hemophilia A/B, lupus anticoagulant
↑ PT & aPTT	DIC, liver failure, vitamin K deficiency, massive transfusion
↑ TT	Heparin effect, dysfibrinogenemia
↓ Fibrinogen	Late DIC, liver disease, fibrinolysis
↑ D-dimer	Thrombosis, PE, DIC, sepsis

🧠 In DIC, you often see: ↑ PT, ↑ aPTT, ↑ D-dimer, ↓ fibrinogen, ↓ platelets

🧪 The Mixing Study (50:50 Test)

Used to differentiate factor deficiency from inhibitor (e.g., lupus anticoagulant, factor inhibitor)

Mixing Study Result	Interpretation
Corrects	Factor deficiency (e.g., hemophilia)
Does not correct	Inhibitor present (e.g., lupus anticoagulant)

⚠️ Always perform in cases of isolated prolonged aPTT with no clear explanation.

🧠 Viscoelastic Testing (TEG / ROTEM)

These bedside tools give real-time, dynamic evaluation of clot formation and breakdown.

Parameter	What It Reflects
R time	Time to clot initiation (like PT/aPTT)
K time	Clot formation rate (fibrin buildup)
Alpha angle	Fibrinogen activity + speed of clot strength
MA (Maximum Amplitude)	Clot strength (platelets + fibrinogen)
LY30	Clot lysis at 30 min (fibrinolysis)

🧪 TEG/ROTEM is especially useful in:

Trauma
Liver transplant
OB hemorrhage
ECMO & cardiac surgery
DIC evaluation

🔎 Clinical Pearls

Always recheck abnormal labs — lab errors and dilutional effects are common
If PT and aPTT are both normal, don’t assume normal coagulation in: ▫️ Liver disease
▫️ Antiplatelet drugs
▫️ Qualitative platelet dysfunction
Viscoelastic tests are valuable in dynamic coagulopathy — but depend on skill and access

3️⃣ Approach to Bleeding in the ICU

From chaos to clarity — a structured decision-making model.

🩸 When the ICU Bleeds

Bleeding in the ICU may be:

Spontaneous: epistaxis, mucosal, GI, hematuria
Procedure-related: line insertions, surgery, tracheostomy
Ongoing hemorrhage: trauma, obstetrics, DIC, ECMO

The goal is not just to stop bleeding, but to identify and correct the cause rapidly.

🧠 Stepwise Bedside Approach (5C’s)

Confirm the Bleed ▫️ Is it true bleeding or discoloration/infiltrate?
▫️ Active? Sentinel? Oozing?
Check Vital Organs ▫️ GCS, MAP, HR, lactate, shock index
▫️ Signs of cerebral, pulmonary, cardiac, or GI compromise?
Count & Coags ▫️ CBC (platelets, Hb)
▫️ PT/INR, aPTT, fibrinogen, D-dimer
▫️ TEG/ROTEM if available
▫️ Repeat if diluted or affected by massive fluids
Classify the Cause ▫️ Platelet (quantitative vs qualitative)
▫️ Coagulation factor deficiency
▫️ Hyperfibrinolysis
▫️ Combined (e.g., DIC, trauma)
Correct with Purpose ▫️ Targeted product + hemodynamic stabilization
▫️ Don't transfuse blindly

🚩 Red Flags in the Bleeding ICU Patient

Red Flag	Implication
Drop in Hb >2 g/dL in 6 hr	Active internal bleeding
Oozing from IV/cannula sites	Suggests DIC or severe thrombocytopenia
Bleeding + renal failure	Think uremic platelet dysfunction
High INR + normal aPTT	Factor VII loss → liver disease/warfarin
Bleeding post-heparin	Evaluate for HIT if platelets ↓ >50%

🧃 Transfusion Thresholds (General ICU)

Product	Threshold to Consider Transfusion
Platelets	<50K if bleeding or surgery; <100K in neurosurgery
FFP	INR >1.5 with bleeding or procedure
Cryoprecipitate	Fibrinogen <1.5 g/L (<2.0 in obstetrics/trauma)
RBCs	Hb <7 g/dL (higher in active bleeding or ischemia)

🧠 Target the deficit, not just the lab number. Transfuse what’s missing.

🩺 Sample ICU Case Flow

🧪 Case: 67-year-old on warfarin with GI bleeding
➡️ PT/INR 4.2, Platelets 180, Fibrinogen 2.4
🧾 Plan:
- Hold warfarin
- Give vitamin K 10 mg IV
- PCC (preferred over FFP for rapid reversal)
- Monitor for rebleed and INR trend

🧠 Tips from Real Practice

✅ Always repeat coags after 6–8 units of blood or high-volume saline
✅ Use viscoelastic testing if conventional labs don’t explain bleeding
✅ Don’t delay action waiting for lab results if clinically obvious bleeding
✅ In cirrhosis, INR may be elevated but does not always reflect bleeding risk — assess clinically

With honor, depth, and precision — here is your fully expanded:

4️⃣ Thrombocytopenia in the ICU — Diagnosis & Management

A fall in numbers with a rise in danger.

📉 What Is Thrombocytopenia?

Defined as a platelet count <150,000/μL.
In ICU, urgency rises when platelets fall below:

<100K in high-risk procedures (e.g. spinal, craniotomy)
<50K if active bleeding or surgery
<20K for spontaneous mucosal bleeding
<10K warrants urgent transfusion, even without bleeding

🔍 ICU Causes — Classified by Mechanism

Mechanism	Common ICU Causes
Decreased production	Sepsis, marrow suppression, chemotherapy, drugs (e.g. linezolid)
Increased destruction	DIC, HIT, TTP, ITP, ECMO
Sequestration	Cirrhosis with splenomegaly
Dilutional	Massive transfusion, fluid overload

🕒 Timeframe of Drop — Clinical Clues

Onset Timing	Suspicion
<48 hours	Sepsis, pre-existing, dilutional
Day 4–10 post-heparin	Strongly suspect HIT
Sudden + hemolysis	Consider TTP

🧨 4.1 Heparin-Induced Thrombocytopenia (HIT)

An immune-mediated, prothrombotic condition due to heparin-PF4 antibodies.

🎯 When to Suspect HIT

Platelet drop >50% from baseline
Timing: Day 5–10 after exposure
New thrombosis or skin necrosis
No alternative explanation

🔎 Use the 4Ts Score

Criterion	Scoring
Thrombocytopenia	>50% drop = 2 pts
Timing	Day 5–10 = 2 pts
Thrombosis	New/proven = 2 pts
Other causes	None evident = 2 pts

Score 6–8: High probability → act immediately
Send PF4 ELISA and/or SRA (gold standard)

🚫 Do NOT

Continue any form of heparin
Transfuse platelets unless bleeding is life-threatening

✅ Do

Switch to non-heparin anticoagulant (argatroban, fondaparinux, bivalirudin)
Bridge to warfarin after platelets recover

🎯 4.2 Immune Thrombocytopenic Purpura (ITP)

An autoimmune attack on platelets, usually isolated thrombocytopenia.

🧪 Diagnosis

Platelets <30,000/μL
Normal PT/aPTT
No schistocytes, no hemolysis
Secondary causes: HIV, HCV, SLE, CLL

➡️ Diagnosis of exclusion

💉 Treatment

Option	Dose / Notes
Steroids	Prednisone 1 mg/kg/day or Methylpred 1 g/day x 3
IVIG	1 g/kg/day x 2
Platelets	Only if life-threatening bleed
Rituximab	Chronic or refractory ITP
Splenectomy	For steroid and IVIG failures (durable remission)

⚠️ 4.3 Thrombotic Thrombocytopenic Purpura (TTP)

A hematologic emergency due to ADAMTS13 deficiency → ultra-large vWF → microthrombi.

🧠 Classic Pentad

(<10% present fully in ICU)

Thrombocytopenia
Microangiopathic hemolytic anemia (MAHA)
Neurological signs (confusion, seizures)
Renal failure
Fever

Most ICU cases present with thrombocytopenia + hemolysis only

🔬 Labs

Test	Result
Platelets	<20–30K
Hemoglobin	↓ + schistocytes
LDH, indirect bilirubin	↑↑ (hemolysis)
Haptoglobin	↓
PT/aPTT	Often normal
ADAMTS13	<10% confirms (send but don’t wait)

🚨 Management

Intervention	Note
Plasma exchange (PEX)	Daily until platelets recover
Steroids	Methylpred or prednisone
Rituximab	For severe or relapsed cases
Caplacizumab	Rapid-acting anti-vWF (if available)
Platelets	🚫 Avoid — risk of thrombosis unless bleeding to death

📦 Clinical Pearl — ITP vs. TTP

🧠 When every platelet counts, knowing the enemy matters.

Feature	🟡 ITP	🔴 TTP
Etiology	Autoimmune platelet destruction	ADAMTS13 deficiency → platelet microthrombi
Pathology	Peripheral destruction by antibodies	Microvascular thrombosis with MAHA
Platelet Count	Often <30K, may be <10K	<20–30K
Hemolysis (MAHA)	❌ Absent	✅ Present — schistocytes, ↑LDH, ↓haptoglobin
Neurological Signs	❌ Rare	✅ Common — confusion, seizures, AMS
Renal Dysfunction	❌ Uncommon	✅ Common
PT / aPTT	Normal	Normal
Peripheral Blood Smear	Normal	Schistocytes
ADAMTS13 Level	Normal	↓↓↓ (<10%)
Treatment (1st-line)	Steroids, IVIG	Plasma exchange + Steroids
Platelet Transfusion	✅ If bleeding	🚫 Avoid unless life-threatening
Mortality Untreated	Low	⚠️ High (~90%)

🧠 Clinical Tip + Decision Point:

If a critically ill patient presents with thrombocytopenia, anemia, neurologic changes, and renal dysfunction — always suspect TTP.
Start plasma exchange immediately, even before ADAMTS13 results.
❗ Delays in treatment can be fatal.

💉 4.4 Platelet Transfusion — Thresholds & Response

Clinical Context	Target Count
Spontaneous bleeding	>20K
Active/procedural bleed	>50K
Neurosurgery/spinal/eye	>100K
HIT/TTP	🚫 Avoid unless emergency bleed

🧪 Dose Guide

Type	Amount	Expected ↑
Apheresis unit	1 unit (3×10¹¹ platelets)	+30–60K/μL
Pooled random donors	4–6 units	+30–50K/μL
Pediatric	10 mL/kg	+30–60K/μL

➡️ Recheck platelet count 1 hour post-transfusion

⚠️ If no rise after 2 transfusions → suspect:

DIC or ongoing consumption
Alloimmunization → use HLA-matched platelets

5️⃣ Inherited Coagulation Disorders

When genes bleed — precision is the cure.

🔬 Overview

Inherited coagulation disorders are quantitative or qualitative deficiencies of coagulation factors, most notably:

Hemophilia A (Factor VIII deficiency)
Hemophilia B (Factor IX deficiency)
von Willebrand Disease (vWD)
Others: Factor XI deficiency, rare factor variants (e.g., V, VII)

Though often diagnosed early, many adult patients present to the ICU due to trauma, surgery, or spontaneous bleeds — especially if undiagnosed or poorly managed.

🧬 Hemophilia A & B

Feature	Hemophilia A	Hemophilia B
Deficiency	Factor VIII	Factor IX
Prevalence	~1 in 5,000 males	~1 in 30,000 males
Inheritance	X-linked recessive	X-linked recessive
Severity (Factor level)	Severe <1%, Moderate 1–5%, Mild 6–40%	Same criteria

🧠 Clinical Features

Hemarthrosis (knees, ankles, elbows)
Muscle hematomas
CNS bleeds (even after minor trauma)
Retroperitoneal bleeds
Delayed post-op or dental bleeding

💉 Factor Replacement — Precise Dosing

✅ Goal: Raise factor level to safe threshold depending on the bleed

🔹 Factor VIII (Hemophilia A)

Target Factor Level	Clinical Context	Dosing
30–50%	Minor bleed / dental	10–15 IU/kg IV q12h
50–100%	Major bleed / surgery	25–50 IU/kg IV q8–12h
CNS / life-threatening	100%	50 IU/kg loading, then 25 IU/kg q8h

🧮 Formula:
1 IU/kg = ↑ Factor VIII by ~2%
So, to raise by 100% → 50 IU/kg

🩺 Preoperative Factor VIII Replacement Strategy

Targeted correction before major surgery in Hemophilia A

📍 Why Preoperative Correction Is Critical

In Hemophilia A, patients often present to the OR with low or undetectable Factor VIII levels, placing them at high risk of surgical hemorrhage, hematoma formation, or catastrophic CNS or airway bleeding.

Even mild hemophilia (6–40%) requires correction prior to invasive procedures.

🎯 Target Factor VIII Activity Before Surgery

Surgical Context	Target Activity
Minor procedure (e.g., dental)	20–30%
Moderate risk (e.g., endoscopy, biopsy)	30–40%
Major surgery (e.g., laparotomy, ortho, trauma)	50–100%
CNS, thoracic, or life-threatening bleeding	100%

🧠 30–40% is the minimum threshold for stable clot formation during general surgery.

🧬 Dosing Formula Recap

1 IU/kg = ↑ 2% Factor VIII activity
Half-life: 6–10 hours
Dosing: Typically 25–50 IU/kg IV pre-op
Maintenance: q8–12h post-op to maintain target

🔢 Clinical Example

Patient: 70 kg male with 10% baseline Factor VIII
Target for surgery: 40%
Required increase: 30%

Dose = 15 IU/kg × 70 kg = 1,050 IU

💉 Product Equivalents

Product	Typical Content	Amount Needed
FFP	225 IU per 225 mL	~5 units
Cryoprecipitate	50–100 IU per 10 mL	~10–20 units
Factor VIII concentrate	40 IU/mL	~26 mL (1,050 ÷ 40)

✅ Factor VIII concentrate preferred for precision
⚠️ FFP/cryoprecipitate may be used only if concentrate unavailable

🧠 Clinical Notes

Recheck Factor VIII activity levels post-loading dose
Watch for inhibitor resistance (if no response to usual dosing)
Continue maintenance doses postoperatively x 5–7 days for major surgery

🔹 Factor IX (Hemophilia B)

Target Factor Level	Clinical Context	Dosing
30–50%	Minor bleed / dental	25–30 IU/kg IV q24h
50–100%	Major bleed / surgery	40–60 IU/kg IV q24h
CNS / critical	100%	Loading 80–100 IU/kg, then q24h

🧮 Formula:
1 IU/kg = ↑ Factor IX by ~1%
So, to raise by 100% → 100 IU/kg

💠 Monitoring

Check factor levels every 12–24 hours if severe bleed
Adjust for inhibitors if poor response (especially in Hemophilia A)
Avoid IM injections and NSAIDs

🧬 Inhibitor Development

Seen in 25–30% of Hemophilia A patients
Consider if no response to standard dosing
Requires:
- Bypassing agents: FEIBA, recombinant FVIIa
- Hematology consult

💧 Cryoprecipitate — Use in Emergencies

Contains Factor VIII, vWF, fibrinogen, Factor XIII
Useful when specific factor is unavailable
Dose: 1 unit/10 kg body weight
Each unit raises fibrinogen by ~0.5 g/L

🧠 Not used for Factor IX — contains negligible amounts.

💊 Desmopressin (DDAVP)

Stimulates release of Factor VIII & vWF from endothelium
Effective in mild Hemophilia A and Type 1 vWD
Dose: 0.3 mcg/kg IV over 20–30 minutes
Effect lasts ~6–8 hours
Caution: May cause hyponatremia

6️⃣ Acquired Coagulopathies in Critical Care

Not born to bleed — but pushed to the edge.

These disorders are common in the ICU, highly dynamic, and often multifactorial, arising from:

Sepsis
Organ failure (liver, kidney)
Malignancy
Shock
Massive transfusion

⚠️ 6.1 Disseminated Intravascular Coagulation (DIC)

A consumptive, systemic activation of coagulation leading to:

Microvascular thrombosis
Followed by bleeding from factor & platelet depletion

🔍 Causes of DIC

Sepsis (gram-negative > gram-positive)
Trauma, burns
Obstetrics: abruption, AFE, retained fetal parts
Malignancy (APL, pancreatic, GI, prostate)
Snake bites, severe COVID-19

🧪 Diagnosis — ISTH DIC Scoring System

Parameter	Score
Platelet count	≥100K = 0; <100K = 1; <50K = 2
Elevated D-dimer/fibrin split products	Moderate ↑ = 2; Strong ↑ = 3
Prolonged PT	>3 sec = 1; >6 sec = 2
Fibrinogen	<1.0 g/L = 1; normal = 0

➡️ Score ≥5 = Overt DIC

🧠 DIC Labs Summary

Test	Finding in DIC
Platelets	↓↓↓
PT / aPTT	Prolonged
D-dimer	↑↑↑
Fibrinogen	↓ (late)
Smear	Schistocytes (in severe DIC)

✅ DIC Overview (Section 6.1 Highlights)

🔬 Pathophysiology:

Systemic coagulation activation → microthrombi
Followed by consumption of clotting factors and platelets → bleeding

📋 Common Triggers:

Sepsis (esp. gram-negative)
Obstetric emergencies (AFE, abruption)
Trauma, burns
Malignancy (APL, GI, pancreatic)
Severe COVID-19, snake bites

🧪 Diagnosis: ISTH DIC Scoring Table

Included full scoring with:

Platelet count
D-dimer
PT prolongation
Fibrinogen level
→ Score ≥5 = Overt DIC

✅ Also included lab features:

Thrombocytopenia
↑ PT/aPTT
↓ fibrinogen (late)
↑↑ D-dimer
Schistocytes (in severe cases)

🛠️ Management Table:

Step	Intervention
Treat underlying cause	Sepsis, malignancy, OB, trauma
Platelets <50K + bleeding	1 unit apheresis platelets
INR >1.5 + bleeding	FFP 10–15 mL/kg
Fibrinogen <1.5 g/L	Cryoprecipitate or fibrinogen concentrate
Active bleeding	Repeat labs & correct q6–12h
Thrombosis-dominant DIC	Consider heparin if no major bleeding

🧠 Monitor platelets, INR/PTT, fibrinogen, D-dimer q12–24h

🧬 6.2 Liver Disease-Related Coagulopathy

The liver produces most clotting factors, fibrinogen, antithrombin, and clears activated factors.

⚠️ Coagulopathy in Liver Failure Is Complex

Both bleeding and thrombotic risk coexist
INR is unreliable alone — does not reflect true bleeding risk
TEG/ROTEM is often more predictive than INR

💡 Correction Strategy in Liver-Related Bleeding

Issue	Treatment
↑ INR >1.5 + bleeding	FFP 10–15 mL/kg
Fibrinogen <1.5 g/L	Cryoprecipitate or fibrinogen concentrate
Platelets <50K	Platelet transfusion
Refractory cases	rFVIIa (last resort; high thrombotic risk)

🧫 6.3 Uremic Platelet Dysfunction

Seen in acute and chronic renal failure — platelet number may be normal, but function is impaired.

🔍 Diagnosis

Bleeding time ↑
Platelet count: normal or mildly low
PTT/INR: normal

🧠 Clues

Oozing from line sites
GI or mucosal bleeds
Dialysis-dependent patients with no obvious cause

💉 Management

Treatment	Mechanism
Desmopressin (DDAVP)	↑ vWF release from endothelium
Dialysis	Removes uremic toxins
Cryoprecipitate	Provides vWF, fibrinogen
Tranexamic acid (TXA)	In mucosal bleeds (e.g. epistaxis)
🚫 Avoid	NSAIDs, antiplatelet agents

7️⃣ Anticoagulant-Associated Coagulopathy

When lifesaving medications turn into bleeding threats.

These cases are increasingly common, especially in elderly, cardiac, or post-thrombotic patients on:

Warfarin
Direct oral anticoagulants (DOACs)
Unfractionated heparin (UFH)
Low-molecular-weight heparin (LMWH)

🧨 7.1 Warfarin-Associated Bleeding

🧠 Pathophysiology

Inhibits vitamin K-dependent clotting factors (II, VII, IX, X) → ↑ PT/INR

🔬 Interpretation

INR Range	Bleeding Status	Management
INR 3–5	No bleeding	Hold warfarin, ± oral vitamin K (1–2.5 mg)
INR >5–9	No bleeding	Oral vitamin K 2.5–5 mg
INR >9	No bleeding	Oral vitamin K 5–10 mg, hold warfarin
Any INR + bleeding	Minor or major	IV vitamin K + PCC or FFP if PCC unavailable

💉 Reversal Regimens

Reversal Agent	Dose
Vitamin K (IV)	10 mg slow IV over 30 minutes (risk of anaphylaxis)
PCC (4-factor)	See table below — faster and preferred
FFP	10–15 mL/kg if PCC unavailable

📏 PCC Dosing for Warfarin (based on INR)

INR	PCC Dose (IU/kg)
2–4	25 IU/kg
4–6	35 IU/kg
>6	50 IU/kg

➡️ Max: usually 3,000 IU
➡️ Always give with IV vitamin K

💊 7.2 DOAC-Associated Bleeding (Apixaban, Rivaroxaban, Dabigatran)

These drugs do not affect INR, so monitoring and reversal are nuanced.

📋 General Principles

Agent	Mechanism	Half-Life	Monitoring
Apixaban	Xa inhibitor	~12 hours	Anti-Xa (not routine)
Rivaroxaban	Xa inhibitor	~9 hours	Anti-Xa (not routine)
Dabigatran	Thrombin inhibitor	~12–17 hours	aPTT / TT (may ↑)

💉 Reversal of DOACs

Drug	Reversal Agent	Dose / Note
Dabigatran	Idarucizumab (Praxbind)	5 g IV (2×2.5 g) over 15 min
Xa inhibitors	Andexanet alfa (Andexxa)	Dose depends on drug + timing
Any DOAC	PCC (off-label if no antidote)	25–50 IU/kg (4-factor PCC)
All agents	Activated charcoal if <2 hr	Oral dose 50 g
Dabigatran	Hemodialysis	Effective in life-threatening cases

⚠️ Andexanet is costly, limited in availability, and may increase thrombotic risk.

🧪 7.3 Heparin & LMWH Reversal

Agent	Reversal Strategy
UFH	Stop drug (short t½ ~1 hr)
	Protamine sulfate 1 mg per 100 units UFH (max 50 mg)
LMWH (e.g. enoxaparin)	Protamine sulfate 1 mg per 1 mg of LMWH (if <8 hr) — partial reversal only

⚠️ Protamine side effects: hypotension, bradycardia, anaphylaxis (esp. in diabetics on NPH insulin)

🧠 Red Flags in Anticoagulant Bleeds

Bleeding on warfarin with INR >4 = high risk
DOACs taken within last 4–6 hours → high bioavailability
No available reversal: rely on supportive care + time
Neuraxial anesthesia: always refer to ASRA guidelines for timing!

8️⃣ Coagulopathy in Special Situations

Unique settings. Universal vigilance.

These situations demand tailored hemostatic thinking, as conventional thresholds may fail to predict bleeding or thrombosis.

🔪 8.1 Trauma-Induced Coagulopathy (TIC)

A deadly combination of:

Tissue injury
Shock-induced hypoperfusion
Dilution from resuscitation
Hypothermia + acidosis

🔍 Key Mechanisms

Early fibrinolysis activation
Platelet dysfunction
Endothelial injury
Loss of fibrinogen (often first to drop)

🛠️ Management Principles

Strategy	Details
TXA early	1 g over 10 min → 1 g over 8 hr (if <3h from trauma)
Permissive hypotension	SBP ~90 in non-TBI trauma to limit bleeding
Damage control surgery	For unstable patients — pack, stop, resuscitate
Massive transfusion protocol (MTP)	RBC:FFP:Platelets = 1:1:1
Cryoprecipitate	If fibrinogen <1.5 g/L

🧠 Early TEG/ROTEM can guide product delivery. DIC can evolve later.

🤰 8.2 Obstetric Coagulopathies

📍 a) HELLP Syndrome

Hemolysis
Elevated Liver enzymes
Low Platelets

⬅️ Often seen in preeclampsia patients

Management
Deliver the baby (definitive)
Control BP, MgSO₄
Platelets if <50K and bleeding

📍 b) Amniotic Fluid Embolism (AFE)

A catastrophic, anaphylactoid-like reaction → DIC, shock, and respiratory collapse

Management
Supportive (fluids, vasopressors, oxygenation)
Correct DIC: FFP, platelets, cryo as needed
Early obstetric and ICU team activation

📍 c) Postpartum Hemorrhage + DIC

Consider early TXA (as in WOMAN trial): 1 g IV
Activate obstetric MTP
Uterotonics, surgery, and hysterectomy if needed

💉 8.3 ECMO-Associated Coagulopathy

ECMO circuits activate both coagulation and fibrinolysis.

Common Issues	Monitoring
Heparin over- or underdosing	ACT, anti-Xa
Acquired vWF deficiency	Bleeding + platelet drop
DIC-like picture	Monitor fibrinogen, platelets, D-dimer

Management
Titrate heparin carefully
Replace fibrinogen if <1.5 g/L
Use viscoelastic testing if available
Circuit change if thrombosis present

🛠️ 8.4 Post-Operative Coagulopathy

Especially after:

Cardiopulmonary bypass
Major liver resection
Orthopedic trauma

🔎 Causes

Hemodilution
Hypothermia
Factor consumption
Fibrinolysis

🧠 Rule of 50/100/1.5 in postop bleeds:
✔ Platelets >50K
✔ Fibrinogen >1.5 g/L
✔ INR <1.5

🔧 Reversal Strategy

Abnormality	Correction
Platelets <50K	Transfuse 1 apheresis unit
Fibrinogen <1.5 g/L	Cryoprecipitate or fibrinogen
INR >1.5	FFP (10–15 mL/kg)

9️⃣ Thrombotic vs Hemorrhagic Risk in the ICU

Striking balance — when bleeding and clotting live together.

In the ICU, many patients are at risk for both bleeding and thrombosis simultaneously. Misjudging either can lead to disastrous outcomes.

⚖️ Dual-Edged ICU States

Condition	Thrombosis Risk	Bleeding Risk
Sepsis / DIC	Microthrombi, VTE	GI bleed, cannula sites
COVID-19	VTE, PE, arterial clots	DIC-like bleeding, nose/mucosa
Malignancy	VTE, Trousseau syndrome	Chemo-induced thrombocytopenia
Cirrhosis	Portal vein thrombosis	Variceal, spontaneous
ECMO	Circuit thrombosis	Cannulation, GI, CNS
Major Surgery/Trauma	Post-op VTE	Operative field bleed

🔍 When to Anticoagulate in the ICU?

✅ Do anticoagulate (unless bleeding) in:

Proven DVT or PE
Atrial fibrillation with CHADS-VASC ≥2
Mechanical heart valve
Disseminated thrombosis in DIC
COVID-19 with worsening oxygenation (intermediate-dose)

💉 Dosing in High-Risk ICU Patients

Patient Type	Recommended Strategy
Normal bleeding risk	LMWH standard prophylactic dose
High thrombotic risk (e.g. COVID)	Intermediate dose LMWH
CrCl <30 or unstable	UFH infusion or subcutaneous
Active bleeding	❌ Hold anticoagulation

🧪 Bridging Decisions with Labs

Lab Result	What It Means Clinically
Platelets <50K	Avoid full-dose anticoagulation
Fibrinogen <1.5 g/L	Risk for bleeding
INR >1.5	Caution with anticoagulation
D-dimer ↑↑	May justify anticoagulation (e.g. COVID)

🧠 Risk Stratification Approach

🔄 1. What is the clinical indication to anticoagulate?

VTE, AF, mechanical valve, clot in line, ECMO, etc.

💧 2. What is the current bleeding risk?

Platelet count, INR, fibrinogen, procedure plans

⚙️ 3. Can we mitigate bleeding first?

Transfuse platelets, FFP, cryo before anticoagulation if needed

🚫 4. Are there absolute contraindications?

Uncontrolled intracranial bleed
Hemodynamic instability from hemorrhage

🧠 Clinical Pearl

“In DIC with thrombosis, anticoagulation with heparin may be life-saving.”
“In cancer, thrombosis may precede bleeding. Don’t wait for a clot to act.”

🔟 Management Algorithms & Emergency Protocols

From complexity to clarity — when time matters most.

📊 10.1 General Bleeding Algorithm (Non-surgical, ICU)

Patient Bleeding in ICU → Follow These 5 Steps:

1️⃣ Stabilize:
▫️ ABCs, control external bleeding, consider intubation if altered GCS
▫️ IV access x2 large bore, start fluid/blood resuscitation

2️⃣ Assess Coagulopathy:
▫️ CBC, PT/INR, aPTT, fibrinogen, D-dimer
▫️ Smear (schistocytes?), TEG if available

3️⃣ Classify Cause:
▫️ Platelet? Factor deficiency? DIC? Anticoagulant?

4️⃣ Targeted Correction:
| Abnormality | Correction

Abnormality	Correction Strategy
Platelets <50,000/μL	Transfuse 1 unit apheresis platelets
INR >1.5	Give FFP 10–15 mL/kg
Fibrinogen <1.5 g/L	Administer Cryoprecipitate or fibrinogen concentrate
DOAC-associated bleed	Use PCC 25–50 IU/kg ± antidote (if available)
Warfarin + active bleed	Vitamin K 10 mg IV + PCC (or FFP if PCC unavailable)
Suspected DIC	Transfuse FFP + platelets + cryoprecipitate empirically

🧠 Repeat correction every 6–12 hours based on labs and bleeding status.

5️⃣ Monitor & Reassess:
▫️ Repeat labs q6–12 hrs
▫️ Monitor for rebleed, overcorrection, transfusion reactions

🛠️ 10.2 Massive Transfusion Protocol (MTP)

Indication: ≥10 units PRBC in 24h or ≥3 units in <1h with unstable vitals

📦 Ratio-Based MTP

Component	Target Ratio
PRBCs	1
FFP	1
Platelets	1 (unit per 6 PRBC)

➡️ Add cryoprecipitate early if fibrinogen <1.5 g/L

🧠 Always monitor calcium and temperature during MTP!

📦 Scientific Basis: Why 1 PRBC + 1 FFP + 1 Cryo Makes Sense

Restoring clotting — not just color.

🔬 Understanding the Physiology Behind MTP

🔹 Platelet Dysfunction from Stored Blood

PRBCs and stored whole blood lose functional platelets after 48 hours
After 8–10 units of PRBC, dilutional thrombocytopenia is expected
However, bleeding from mildly low platelets is rare unless:
- <100 × 10⁹/L + active bleeding or pre-op requirement
➤ Routine platelet transfusion is unnecessary
✅ Monitor count & transfuse only when indicated

🔹 Clotting Factor Dilution

Stored whole blood <14 days retains factors — adequate for hemostasis
After 14 days, there is a significant drop in:
- Fibrinogen
- Factor V
Factor VIII may be preserved due to endothelial storage & stress release

💡 Recommended Physiologic Transfusion Matching

Component	Rationale
1 unit PRBC	Replaces red cell mass for oxygenation
1 unit FFP	Replaces multiple coagulation factors
1 unit Cryoprecipitate	Replaces fibrinogen, vWF, Factor VIII
± Platelets	Only if <100K + active bleeding/surgery

➡️ This 1:1:1 approach is a pragmatic way to restore hemostasis, particularly when:

Whole blood is not fresh
Factor concentrates are unavailable
TEG/ROTEM is not available

🧠 Clinical Takeaway

“Hemostasis is not red. It’s balanced.”
Transfusing only red cells in trauma or surgery will leave the patient coagulopathic. Think beyond hemoglobin — think fibrinogen, platelets, and factor balance

🔻 Complications of Massive Blood Transfusion

“Not all blood restores life — some demands it.”

Massive transfusion, defined as the replacement of ≥1 blood volume in 24 hours or ≥10 units PRBC, introduces serious physiological risks beyond bleeding.

1- Dilutional Thrombocytopenia

PRBCs and stored blood >48 hrs contain no viable platelets
After 8–10 units, platelet count typically drops
Bleeding is rare unless <100 × 10⁹/L + active bleeding/surgery
❗ Routine platelet transfusion is not necessary — monitor counts instead

2- Dilution of Coagulation Factors

Whole blood <14 days has sufficient coagulation factors
After 14 days, fibrinogen and factor V drop significantly
Factor VIII likely stored in endothelium and released under stress
Use FFP + cryo to restore balance in stored blood transfusion

3- Hypothermia (Core Temp <35°C)

Occurs with rapid transfusion of cold blood or large-volume fluids
Can trigger arrhythmias, especially ventricular fibrillation (VF)
🛠️ Use blood warmers — especially in trauma or during MTP

4- Citrate Toxicity → Hypocalcemia & Hypomagnesemia

Citrate in stored blood binds ionized calcium & magnesium
Occurs with:
- Rapid transfusion >100 mL/min
- Neonatal exchange transfusions
Leads to:
- Hypocalcemia → hypotension, QT prolongation, Torsades
- Early metabolic acidosis, later metabolic alkalosis from citrate metabolism
✅ Monitor ionized Ca²⁺ and give IV calcium gluconate if symptomatic

5- Acid-Base Imbalance

Lactic acid and citrate in stored PRBC can cause:
- Early: Metabolic acidosis
- Later: Alkalosis (as citrate metabolizes to bicarbonate)
Monitor ABG trends in large-volume transfusions

6- Hyperkalemia

Potassium leaks from aging RBCs into the storage solution
Rapid transfusion may deliver large K⁺ bolus → arrhythmias
Risk ↑ with:
- Blood stored >7–10 days
- 100 mL/min transfusion rate
- Acidotic patients who cannot shift K⁺ into cells

🛠️ Use fresh or washed RBCs in neonates, massive transfusion, renal failure

7- Volume Overload (TACO)

Excess volume → pulmonary edema, ↑ CVP, hypoxia
Especially in:
- Elderly
- Renal or cardiac failure
Prevent with diuretics, fluid tracking, and slow infusion if not bleeding

8- Thrombosis & Air Embolism

Central lines under negative pressure + air = risk of venous air embolism
Rapid infusion through faulty lines may promote venous thrombosis
Ensure air-free circuits, use air filters if available

9- High Oxygen-Affinity Blood → Tissue Hypoxia

Stored RBCs have low 2,3-DPG, shifting Hb-O₂ curve leftward
O₂ is bound tightly to hemoglobin but poorly released to tissues
Reoxygenation is deceptive — tissues remain hypoxic

🧠 Clinical Pearl:

“Massive transfusion is not just volume replacement — it's metabolic warfare. Know the enemy.”

⚕️ 10.3 Warfarin Reversal Protocol

Scenario	Treatment
INR >4 + minor bleed	Vitamin K PO 2.5–5 mg
INR >6 or any serious bleed	Vitamin K IV 10 mg + PCC based on INR
INR >10, no bleed	Vitamin K PO 5–10 mg, hold warfarin

🧬 10.4 DIC Emergency Protocol

Findings	Action
Platelets <50K	1 unit apheresis platelets
INR >1.5	FFP 10–15 mL/kg
Fibrinogen <1.5 g/L	Cryoprecipitate 1–2 pools or fibrinogen conc.
Active bleeding	Repeat dosing every 6–8 hours as needed

📖 10.5 HIT Management Flow

1️⃣ Suspect HIT (4Ts ≥4)
2️⃣ Stop all heparin (including flushes)
3️⃣ Send PF4 antibodies + SRA
4️⃣ Start non-heparin anticoagulant
▫️ Argatroban (renal OK) or fondaparinux (hepatic OK)
5️⃣ Transition to warfarin only when platelets >150K

🔻 10.6 Clinical Clarifications: FFP, Platelets & Heparin Use

“Don’t assume — understand the mechanism.”

❓ Can we use FFP to reverse Heparin?

🔴 No.
Fresh Frozen Plasma contains Antithrombin III (ATIII) — the precise cofactor that enhances heparin's anticoagulant effect.
➡️ Administering FFP in this setting may potentiate heparin rather than reverse it.

✅ Use Protamine Sulfate to antagonize heparin (1 mg neutralizes ~100 units UFH).

❓ Should we give FFP and platelets routinely in massive transfusion?

🔴 No — not without indication.

FFP should be given based on PT/aPTT/fibrinogen, not by default
Platelets only required if:
- <50,000/µL with bleeding
- <100,000/µL with surgery or active hemorrhage

🧠 Unnecessary transfusion increases risk of volume overload and TRALI without benefit.

❓ How do we treat Heparin Resistance?

✅ Administer FFP to restore Antithrombin III levels
In patients who fail to achieve therapeutic aPTT despite escalating heparin doses:

Suspect ATIII deficiency
Give FFP (2–4 units) to replenish ATIII
Then heparin becomes effective

🧠 Seen in: Sepsis, critical illness, liver disease, ECMO patients

📌 These insights are vital in massive transfusion, heparin monitoring, and emergency bleeding scenarios — always individualize based on labs and physiology, not protocol alone.

1️⃣1️⃣ Managing Coagulopathy in Limited-Resource Settings

When the ideal is out of reach — clinical wisdom becomes the lifeline.

🧭 Key Challenges

❌ No access to PCC, recombinant factors, or TEG
❌ Delayed or unavailable labs (PT/INR, fibrinogen, D-dimer)
❌ Blood products may be scarce or unsafe
❌ Inadequate storage (cold chain for cryo/FFP)

Yet — critical bleeding must be managed.
This section focuses on decision-making without waiting.

🧠 Stepwise ICU Approach When Labs Are Delayed

1️⃣ Clinical Clues First

Gum, GI, and surgical site bleeding → suspect platelet or fibrinogen problem
Diffuse oozing + prolonged bleeding time → think DIC or uremic dysfunction
Sudden neuro signs + low GCS → treat as life-threatening bleed

2️⃣ Pragmatic Transfusion Targets

Scenario	Actionable Thresholds
Suspected DIC	Give platelets + FFP empirically
Unexplained prolonged bleed	Start vitamin K empirically
Surgical/pre-op + bleeding	Transfuse FFP + platelets if available
Fibrinogen suspected low	Give cryoprecipitate if available (1 unit/10 kg)

🔄 Alternative Therapies When Products Are Unavailable

Goal	If Standard Unavailable	Substitute Strategy
Factor replacement (VIII/IX)	No recombinant factor	FFP or Cryo (may need large volumes)
vWF support	No DDAVP available	Cryoprecipitate (contains vWF + VIII)
Platelet transfusion	No donor units	FFP may help marginally, or delay surgery
Fibrinogen <1.5 g/L	No cryo or fibrinogen conc.	FFP at 15–20 mL/kg (modest fibrinogen gain)
INR >1.5 + bleed	No lab confirmation	Give FFP empirically if actively bleeding

🩸 Using Tranexamic Acid (TXA) as a Lifesaver

✅ Widely available
✅ Cheap
✅ Minimal monitoring needed

| Dose: 1 g over 10 min → 1 g over 8 hours (IV infusion)
| Use in:

Trauma
Postpartum hemorrhage
Mucosal or surgical bleeds
Suspected early DIC (not thrombotic stage)

🔥 Pearl: Simplified DIC Response Without Labs

In massive bleeding with clinical suspicion of DIC:
Give 2 units FFP + 1 apheresis platelet + 1 pool cryo, then reassess

1️⃣2️⃣ High-Yield Drug Doses & Correction Tables

A single glance to guide your next move.

🩸 Blood Component Transfusion — Quick Reference

Product	Standard Dose	Effect
Platelets (apheresis)	1 unit (3×10¹¹ platelets)	↑ Platelets by 30–60K/μL
Pooled platelets	4–6 random donor units	↑ Platelets by 30–50K/μL
FFP	10–15 mL/kg	↓ INR, ↑ Factors (esp. II, V, VII, IX)
Cryoprecipitate	1 unit/10 kg (typically 10 units/pool)	↑ Fibrinogen by ~0.5–1.0 g/L
PRBCs	1 unit	↑ Hb ~1 g/dL

🔹 Blood Components — Quick ICU Summary

A reference grid for safe, effective transfusion decisions.

🧃 1. Packed Red Blood Cells (PRBCs)

Property	Details
Volume	~300 mL (with additive solution)
Hematocrit	~60%
Storage	4°C, up to 42 days
Effect	↑ Hb ~1 g/dL per unit (2–3% Hct)
Compatibility	ABO compatible required
Special Notes	Contains no platelets or clotting factors; limited 2,3-DPG → delayed O₂ delivery in older units

💧 2. Fresh Frozen Plasma (FFP)

Property	Details
Volume	200–250 mL
Storage Temp	−20 to −30°C (thawed before use)
Dosing	10–15 mL/kg for bleeding/coagulopathy
Effect	↑ clotting factors to ~30% normal
Reversal Use	Used for warfarin support, not rapid reversal
Compatibility	ABO compatible; Rh not required
Note	Low in fibrinogen; combine with cryo if fibrinogen <1.5 g/L

❄️ 3. Cryoprecipitate

Property	Details
Volume	10–15 mL per unit
Content per unit	Fibrinogen (250–600 mg), Factor VIII (80–150 IU), vWF, Factor XIII
Dosing	~1 unit per 10 kg (~10–15 units for adult)
Use	Fibrinogen <1.5 g/L, vWD, Hemophilia A (if no concentrate)
Compatibility	ABO not essential
Note	Small volume, high concentration of fibrinogen — essential in trauma & OB hemorrhage

🧬 4. Platelets

Property	Details
Volume	50–70 mL (per unit)
Dose	1 unit raises count ~5–10 × 10⁹/L 1 apheresis unit raises platelets by ~30–60 × 10⁹/L
Transfusion Goal	Maintain >50K for bleeding, >100K for surgery
ABO Compatibility	Preferred, not essential (may shorten survival)
Storage Temp	22°C; shelf-life 4–5 days
Notes	Avoid if platelet destruction (e.g., ITP); ineffective in antibody-mediated thrombocytopenia

🧠 Teaching Pearls

PRBCs restore oxygenation, not coagulation
FFP restores clotting factors (but not fibrinogen efficiently)
Cryo is ideal for fibrinogen replacement
Platelets should be used only with thrombocytopenia + bleeding/surgery

💉 Factor Replacement Dosing

🔹 Factor VIII (Hemophilia A)

Formula: 1 IU/kg = ↑ Factor VIII by 2%
Goal: Raise to 30–100% depending on bleed
Dose: 25–50 IU/kg IV q8–12h

🔹 Factor IX (Hemophilia B)

Formula: 1 IU/kg = ↑ Factor IX by 1%
Dose: 50–100 IU/kg IV q12–24h

💉 Vitamin K Dosing

Route	Dose	When to Use
Oral	2.5–10 mg	Mild INR ↑, no bleeding
IV (slow push)	10 mg over 30 minutes	Active bleed or high INR
SC / IM	⚠️ Not recommended routinely	Erratic absorption or hematoma risk

💊 Reversal Agents for Anticoagulants

Drug	Antidote / Agent	Dose
Warfarin	PCC + Vitamin K	PCC 25–50 IU/kg + Vit K 10 mg IV
Dabigatran	Idarucizumab	5 g IV (2 doses of 2.5 g)
Rivaroxaban/Apixaban	Andexanet alfa	See weight/timing table (or PCC 50 IU/kg off-label)
UF Heparin	Protamine	1 mg per 100 units heparin
Enoxaparin	Protamine (partial reversal)	1 mg per 1 mg LMWH if <8 hrs

🧠 Fibrinogen Repletion

Agent	Dose	Target Fibrinogen
Cryoprecipitate	1 pool (10 units)	↑ ~0.5–1.0 g/L
Fibrinogen conc.	30–60 mg/kg	Aim >1.5–2.0 g/L (esp. trauma, OB)

🧪 Mixing Study Interpretation Table

Test Outcome	Interpretation
PT/aPTT corrects with mixing	Factor deficiency
PT/aPTT does NOT correct	Inhibitor present (e.g., lupus anticoagulant, factor inhibitor)

1️⃣3️⃣ Pocket Summary & Mnemonics

Recall in a heartbeat. Decide in a second.

📋 Key Transfusion Thresholds

Scenario	Threshold
Spontaneous bleeding	Platelets >20K
Minor surgery	Platelets >50K
Neurosurgery or eye surgery	Platelets >100K
Fibrinogen repletion	Target >1.5–2.0 g/L
INR correction with bleeding	Target <1.5 with FFP

🧠 Mnemonics to Master

💥 DIC Scoring – "DIC-FP"

D: D-dimer ↑
I: INR/PT prolonged
C: Count (platelets ↓)
F: Fibrinogen ↓
P: Peripheral smear → schistocytes

➡️ Score ≥5 = Overt DIC (ISTH criteria)

💉 HIT – "4Ts"

➡️ Score ≥6 = High probability → stop heparin immediately

🚨 TTP Red Flags – "FAT RN"

Classic Pentad

Fever
Anemia (MAHA)
Thrombocytopenia
Renal dysfunction
Neurologic signs

➡️ Often only MAHA + thrombocytopenia seen in ICU
➡️ Start PEX immediately

🩸 Cryoprecipitate Contains – "FAV F13"

Factor VIII
Anti-hemophilic factor
Von Willebrand factor
Fibrinogen
13: Factor XIII

💊 Warfarin Reversal – "PIV":

PCC
IV Vitamin K
Value the INR (guide dosing)

🧪 Mixing Study Mnemonic – "Corrects = Cut, No Correction = Curse"

Corrects → factor deficiency
Does not correct → inhibitor (e.g., lupus, factor antibody)

🧭 One-Line Clinical Pearls

TTP? PEX first. Ask later.
INR ↑? FFP only if bleeding or surgery.
Bleeding in renal failure? Try DDAVP before platelets.
Cirrhotic INR ≠ true bleeding risk — use TEG if available.
DOAC bleed? If no antidote: PCC + time + pray.

1️⃣4️⃣ Advanced MCQ Bank — Coagulopathy in Critical Care

15 scenario-based questions with focused explanations.

✅ MCQ 1

A 56-year-old man with septic shock has platelets 38K, PT 22s, fibrinogen 1.0 g/L, and active oral bleeding. What is the most appropriate next step?

A. Start heparin infusion
B. Platelets + FFP + cryoprecipitate
C. Administer vitamin K only
D. Wait for DIC score before treating

🟩 Answer: B
Explanation: This is overt DIC with bleeding. Give supportive components immediately — don't wait for scores.

✅ MCQ 2

A 62-year-old on warfarin presents with INR 9.8 and epistaxis. BP stable. What is the best management?

A. Hold warfarin, monitor
B. Oral vitamin K only
C. IV vitamin K + PCC
D. FFP only

🟩 Answer: C
Explanation: High INR + active bleeding needs fast reversal: PCC and IV vitamin K.

✅ MCQ 3

A patient post-heparin 6 days ago develops new DVT and platelets drop from 210K → 92K. Next best step?

A. Continue heparin and monitor
B. Stop heparin, send HIT panel, start argatroban
C. Transfuse platelets
D. Switch to LMWH

🟩 Answer: B
Explanation: Classic HIT (timing, drop, thrombosis). Stop all heparin and switch to direct thrombin inhibitor.

✅ MCQ 4

A 28-year-old woman with lupus presents with schistocytes, platelets 22K, Cr 2.3, confusion. Which is most urgent?

A. Start steroids
B. Give platelets
C. Start plasma exchange
D. Transfuse FFP

🟩 Answer: C
Explanation: TTP suspected. Plasma exchange must not be delayed.

✅ MCQ 5

Which blood product is richest in Factor VIII and fibrinogen?

A. FFP
B. Platelets
C. Cryoprecipitate
D. PRBCs

🟩 Answer: C

✅ MCQ 6

Patient with uremia is bleeding post-central line placement. Platelets 150K, INR 1.0. Best first therapy?

A. Platelets
B. DDAVP
C. Vitamin K
D. FFP

🟩 Answer: B
Explanation: Platelets are normal but dysfunctional in uremia — give DDAVP.

✅ MCQ 7

A 76-year-old with new-onset confusion, anemia, thrombocytopenia, and high LDH. Peripheral smear shows schistocytes. What lab confirms diagnosis?

A. Platelet count
B. D-dimer
C. ADAMTS13
D. aPTT

🟩 Answer: C
Explanation: TTP → ADAMTS13 confirms but treatment should start before result.

✅ MCQ 8

Which DOAC has a specific reversal agent approved?

A. Apixaban → Idarucizumab
B. Dabigatran → Idarucizumab
C. Rivaroxaban → Protamine
D. Enoxaparin → Andexanet alfa

🟩 Answer: B

✅ MCQ 9

Cryoprecipitate is NOT effective for which of the following?

A. Hemophilia A
B. Fibrinogen replacement
C. Von Willebrand Disease
D. Hemophilia B

🟩 Answer: D

✅ MCQ 10

A patient with severe GI bleed is on apixaban. No antidote available. Best approach?

A. Wait 24 hours
B. Hemodialysis
C. PCC 50 IU/kg
D. Vitamin K

🟩 Answer: C

✅ MCQ 11

Which of the following is true regarding liver disease coagulopathy?

A. INR predicts bleeding accurately
B. Cryoprecipitate is never needed
C. Fibrinogen is often preserved
D. TEG/ROTEM is better than INR

🟩 Answer: D

✅ MCQ 12

A child with spontaneous joint bleeds, normal platelet count, prolonged aPTT corrected by mixing. Diagnosis?

A. Hemophilia A
B. Factor inhibitor
C. TTP
D. ITP

🟩 Answer: A

✅ MCQ 13

What is the expected rise in fibrinogen after 10 units of cryoprecipitate in a 70-kg adult?

A. 0.5–1.0 g/L
B. 2.0 g/L
C. 0.1 g/L
D. 3.0 g/L

🟩 Answer: A

✅ MCQ 14

Most common inherited bleeding disorder?

A. Hemophilia A
B. Hemophilia B
C. von Willebrand Disease
D. Factor XI deficiency

🟩 Answer: C

✅ MCQ 15

When should TXA be avoided?

A. Postpartum hemorrhage
B. Trauma within 1 hour
C. Upper GI bleed
D. Active DIC with thrombosis

🟩 Answer: D

🧠 Final Words

Coagulopathy in critical care is often the difference between a controlled resuscitation and an uncontrolled catastrophe. This guide provides a structured, detailed, and pragmatic approach — equipping clinicians with the clarity to respond swiftly in hemorrhage, DIC, TTP, anticoagulant emergencies, and transfusion dilemmas.

From factor replacement dosing to massive transfusion protocols, from rural workarounds to viscoelastic strategies, this Mastery Guide is your anchor in complexity.

Our goal is to empower clinicians with structure, clarity, and bedside-ready strategies — whether you’re a critical care provider, anesthesia specialist, internist, or medical educator.

This guide is your reference when facing coagulopathic emergencies — in every setting.
Stay structured. Stay vigilant. Act wisely. 🧠

📌 Prepared for Dr. Amir Fadhel – Specialist in Anesthesiology and Critical Care
📅 Created: 05/06/2025
📅 Last Updated: 06/06/2025

🔗 Explore the Full Mastery Series:
Mastery Series in Anesthesia & Critical Care